Stuart Osborne

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

David Cunningham, István Láng, Eugenio Marcuello et al. · The Lancet Oncology · 2013 · 654 citations

Medicine, Oncology, Pharmacology +10

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

Xavier Pivot, Joseph Gligorov, Volkmar Müller et al. · The Lancet Oncology · 2013 · 226 citations · Full text

Medicine, Oncology, Pharmacology +13

Tegaserod, a 5‐HT ₄ receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects

Lukas Degen, Daniel Matzinger, Michael Merz et al. · Alimentary Pharmacology & Therapeutics · 2001 · 210 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

Xavier Pivot, Joseph Gligorov, Volkmar Müller et al. · Annals of Oncology · 2014 · 176 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab)

Mathias Rummel, T.M. Kim, Franco Aversa et al. · Annals of Oncology · 2016 · 151 citations · Full text

Medicine, Hematology, Oncology +9